PATHFINDER 2: A Multi-Cancer Early Detection Study
← catalyst calendarSponsored by GRAIL, Inc. (industry) · GRAL — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Screening
Enrollment
35,883actual
Sites
56
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-08 | actual | When the study began enrolling |
| Primary completion | 2026-02-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Early Detection of Cancer
- Cancer
Intervention
- Device: Multi-Cancer Early Detection Test
Primary outcomes
what the primary-completion date above is the date OFSafety: Number and type of invasive procedures performed in participants with a cancer signal detected by the multi-cancer early detection (MCED) test and no cancer diagnosis at the time of diagnostic resolution (i.e., false positive test result).
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by positive predictive value (PPV).
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by negative predictive value (NPV).
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by sensitivity.
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by specificity.
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by cancer signal origin (CSO) accuracy.
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by observed cancer detection rate (CDR).
measured Up to 3 Years
Test performance: diagnosis of invasive cancer, assessed by number needed to screen to detect an invasive cancer (NNS).
measured Up to 3 Years
Permalink · GRAL's whole pipeline · Catalyst calendar · Every registered study · What changed